| Trial | Follow Up | Baseline LDL mg/dl (mmol/l) | End Points | Relative Risk Reduction |
| 4S Simvastatin 20 - 40 mg [6] | 5.4 yrs | 188(4.9) | -All cause mortality -NFMI, CHD death | 30% 34% |
| CARE Pravastain 40 mg [7] | 5 yrs | 139(3.6) | NFMI or CHD death | 24% |
| LIPID Pravastatin 40 mg [8] | 6.1 yrs | 150(3.9) | NFMI or CHD death | 24% |
| HPS Simvastatin 40 mg [9] | 5 yrs | 131(3.4) | -All cause mortality -Fatal or nonfatal vascular events | 13% 24% |